4.6 Review

C9orf72loss-of-function: a trivial, stand-alone or additive mechanism in C9 ALS/FTD?

Journal

ACTA NEUROPATHOLOGICA
Volume 140, Issue 5, Pages 625-643

Publisher

SPRINGER
DOI: 10.1007/s00401-020-02214-x

Keywords

C9orf72; Repeat expansion; Amyotrophic lateral sclerosis; Frontotemporal dementia; Loss-of-function; Neurodegeneration; Postmortem; In vitro; In vivo

Funding

  1. VIB
  2. KU Leuven (C1)
  3. KU Leuven (Opening the Future Fund)
  4. Fund for Scientific Research Flanders (FWO-Vlaanderen) [G0C1620N]
  5. Thierry Latran Foundation
  6. Association Belge contre les Maladies neuro-Musculaires-aide a la recherche ASBL (ABMM)
  7. Muscular Dystrophy Association (MDA)
  8. ALS Liga Belgie (A Cure for ALS)
  9. Target ALS
  10. ALS Association (ALSA)

Ask authors/readers for more resources

A repeat expansion inC9orf72is responsible for the characteristic neurodegeneration in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) in a still unresolved manner. Proposed mechanisms involve gain-of-functions, comprising RNA and protein toxicity, and loss-of-function of theC9orf72gene. Their exact contribution is still inconclusive and reports regarding loss-of-function are rather inconsistent. Here, we review the function of the C9orf72 protein and its relevance in disease. We explore the potential link between reduced C9orf72 levels and disease phenotypes in postmortem, in vitro, and in vivo models. Moreover, the significance of loss-of-function in other non-coding repeat expansion diseases is used to clarify its contribution inC9orf72ALS/FTD. In conclusion, with evidence pointing to a multiple-hit model, loss-of-function on itself seems to be insufficient to cause neurodegeneration inC9orf72ALS/FTD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available